Arthneeti
All Q2 FY27 results →
IH

Influx Healthtech Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Influx Healthtech Q2 Results 2026 (FY27): Revenue ₹85.4 Cr, PAT ₹12.0 Cr

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹262
Market cap₹607 Cr
P/E31.8
Updated5 Nov 2026
Read3 min read

Get Influx Healthtech Ltd's next results in your feed

Based on Influx Healthtech Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Revenue from operations for H1 FY27: ₹85.4 crores. EBITDA for H1 FY27: ₹18.3 crores, up 25.1% YoY.

From Influx Healthtech Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.

How did Influx Healthtech's revenue grow in the September 2026 quarter?

  • Revenue from operations for H1 FY27: ₹85.4 crores
  • Year-on-year revenue growth for H1 FY27: +27.9% (vs ₹66.8 crores in H1 FY26)
  • Number of products in H1 FY27: 7 (down from 9 in FY26)
  • Number of clients in H1 FY27: 523 (down from 718 in FY26) but overall strong client base
  • Outlook:
  • FY27 revenue growth target of 25%

2 more points from Influx Healthtech Ltd's call on revenue

Create a free account to keep reading this call

What happened to Influx Healthtech's margins in Q2 FY27?

See what Influx Healthtech Ltd said on profitability & margins — free account, 30 seconds.

What capex is Influx Healthtech planning?

  • ₹29 crores invested to establish a nutraceutical manufacturing facility on a 3,204 mt2 site (page 17).
  • ₹6 crores allocated for a veterinary food manufacturing facility on a 1,350 mt2 site (page 17).
  • ₹2 crores spent on machinery to boost capacity in homecare and cosmetic divisions (page 17).
  • Capacity expansion expected to increase overall capacity by 2.5x post IPO fund utilization (page 17).
  • New 75,000 sq. ft. Palghar facility nearing civil construction completion; interior work and machinery installation underway; commercial production expected in coming months (page 5).
  • Automated beverage manufacturing line with 10,000 bottles/hour capacity, under testing (page 19).
  • Sachet card machine for single-dose packaging introduced (page 19).
  • Retort manufacturing system installed, enabling protein shakes and ready-to-drink products (page 19).

2 more points from Influx Healthtech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Influx Healthtech raising money or cutting debt?

See what Influx Healthtech Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Influx Healthtech's order book?

See what Influx Healthtech Ltd said on order book & pipeline — free account, 30 seconds.

Continue your research

What Influx Healthtech's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Shilpa Medicare Ltd (Q2 FY27)

    2QFY27 total revenue: INR 538 cr, up 45% YoY (from INR 372 cr in 2QFY26). Key investor presentation takeaways from Shilpa Medicare Ltd's Q2 FY27 investor presen

  • Shukra Pharmaceuticals (Q2 FY27)

    For the quarter ended September 30, 2026, revenue from operations is ₹4,420.38 Lakhs compared to ₹587.74 Lakhs for the quarter ended September 30, 2025. Key…

  • Wanbury (Q2 FY27)

    Revenue from operations for the quarter ended 30 September 2026 is ₹18,290.97 Lakhs (₹182.91 Crores). Key results statement takeaways from Wanbury Ltd's Q2 FY27

  • Unichem Laboratories (Q2 FY27)

    Revenue from operations for the quarter ended 30.09.2026 is ₹401.90 crores (standalone) and ₹640.22 crores (consolidated). Key results statement takeaways from

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Influx Healthtech Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Influx Healthtech Ltd Q2 FY27 results?

Revenue from operations for H1 FY27: ₹85.4 crores. EBITDA for H1 FY27: ₹18.3 crores, up 25.1% YoY.

What is Influx Healthtech Ltd share price analysis?

Influx Healthtech Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹607 Cr. Investors should review the full earnings analysis for detailed insights.

Is Influx Healthtech Ltd planning capital expenditure?

₹29 crores invested to establish a nutraceutical manufacturing facility on a 3,204 mt2 site (page 17).

Keep Influx Healthtech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.